| A1059 |
Atoltivimab
Featured
|
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection. |
|
| A1060 |
Muromonab
Featured
|
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection. |
|
| DC67212 |
Acuitas Lipid III-25
Featured
|
Acuitas Lipid III-25 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent US 10,166,298 B2. It is an analgous of ALC-0315, showing higher activity than ALC-0315. |
|
| DC67213 |
Acuitas II-10
Featured
|
Acuitas II-10 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent WO2016176330A1 |
|
| DC67214 |
Acuitas II-12
Featured
|
Acuitas II-12 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent WO2016176330A1 |
|
| DC67215 |
Acuitas Lipid III-7
Featured
|
Acuitas Lipid III-7 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent US 10,166,298 B2. |
|
| DC67216 |
L13
Featured
|
|
|
| DC67217 |
Moderna Lipid compound 46(SM-102 analogue)
Featured
|
Moderna Lipid compound 46 is an novel ionizable amine lipid used for mRNA delivery from Moderna patent WO2017049245A2 |
|
| DC67218 |
Moderna Lipid compound 182
Featured
|
Moderna Lipid Compound 182 is a novel ionizable amine lipid developed by Moderna for the delivery of mRNA-based therapeutics. This lipid is part of Moderna's proprietary lipid nanoparticle (LNP) delivery platform, which is designed to encapsulate and protect mRNA, facilitate its cellular uptake, and enable efficient intracellular release. The ionizable nature of Lipid Compound 182 allows it to interact with mRNA at low pH (during LNP formulation) and release the payload in the neutral pH environment of the cytoplasm, making it a critical component of Moderna's mRNA delivery system. |
|
| DC67219 |
Lipid 29 analogue-3
Featured
|
Lipid 29 analogue-3 is an ionizable lipid designed for the delivery of RNA-based therapeutics, such as mRNA or siRNA. |
|
| DC60732 |
VUF10166
Featured
|
VUF10166 is a potent and high-affinity 5-HT3 receptor antagonist, with Ki values of 0.04 nM (5-HT3A) and 22 nM (5-HT3AB). VUF10166 inhibits 5-HT-induced responses at 5-HT3A and 5-HT3AB receptors at nanomolar concentrations. At 5-HT3 receptor, VUF10166 at higher concentrations also acts as a partial agonist, with an EC50 of 5.2 μM. |
|
| DC60733 |
F-1
Featured
|
F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. |
|
| DC60734 |
MMBC
Featured
|
MMBC is a sulfhydryl-sensitive fluorophore. |
|
| DC60735 |
ATP synthase inhibitor 1
Featured
|
ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels. |
|
| DC60736 |
Mebeverine alcohol
Featured
|
Mebeverine alcohol is a metabolite of Mebeverine, which is a musculotropic antispasmodic drug. |
|
| DC60737 |
Sunitinib
Featured
|
|
|
| DC67220 |
Acuitas Lipid II-10
Featured
|
|
|
| DC60738 |
ROCK inhibitor-2
Featured
|
ROCK inhibitor-2 (compound 6) is a selective dual inhibitor of ROCK1 and ROCK2, with IC50 values of 160 nM and 21 nM, respectively. ROCK inhibitor-2 inhibits pMYPT1 with IC50 of 75 nM. |
|
| DC60739 |
WAY-213613 hydrochloride
Featured
|
WAY-213613 (hydrochloride) is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC50 value of 85 nM. WAY-213613 can be used for the research of central nervous system. |
|
| DC60740 |
DDD107498 succinate
Featured
|
|
|
| DC60741 |
AD57 hydrochloride
Featured
|
AD57 hydrochloride is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src. |
|
| DC60742 |
TAU-IN-1
Featured
|
TAU-IN-1 (compound 051) is a TAU protein inhibitor with an EC50 value of 325 nM. TAU-IN-1 can be used in the study of neurodegenerative diseases. |
|
| DC60743 |
PLpro-IN-1
Featured
|
PLpro-IN-1 (Compound 2) is a SARS-CoV PLpro inhibitor (IC50: 8.7 μM). PLpro-IN-1 can be used for antiviral research. |
|
| DC60744 |
Cotoin
Featured
|
Cotoin is a natural product isolated from the stem bark of Garcinia virgate. |
|
| DC60745 |
CC618
Featured
|
CC618 is a selective peroxisome proliferator-activated receptor (PPARβ/δ) antagonist that exhibits antagonism by covalently binding to PPARβ/δ receptors. |
|
| DC60746 |
SCF29402
Featured
|
|
|
| DC60747 |
BB-22
Featured
|
BB-22 is a third generation SPICE/K2 cannabinoid wih dopamine (DA) stimulant properties. BB-22 shows affinity to CB1 receptors with a Ki value of 0.11 nM and an EC50 value of 2.9 nM. BB-22 also stimulates CB1-induced [35S]GTPγS binding. |
|
| DC60748 |
Zatolmilast
Featured
|
Zatolmilast (BPN14770) is a selective phosphodiesterase 4D (PDE4D) allosteric inhibitor with IC50s of 7.8 nM and 7.4 nM for PDE4D7 and PDE4D3, respectively. |
|
| DC60749 |
Grp94 Inhibitor-1
Featured
|
Grp94 Inhibitor-1 is a potent, selective Grp94 inhibitor with an IC50 value of 2 nM, and over 1000-fold selectivity to Grp94 against Hsp90α. |
|
| DC60751 |
Bevenopran
Featured
|
Bevenopran is a peripheral μ-opioid receptor antagonist. |
|
